Lymph node ratio is a critical prognostic predictor in gastric cancer treated with S-1 chemotherapy

Ema, Akira; Yamashita, Keishi; Sakuramoto, Shinich; Wang, Guoqin; Mieno, Hiroaki; Nemoto, Masayuki; Shibata, Tomotaka; Katada, Natsuya; Kikuchi, Shiro; Watanabe, Masahiko

doi:10.1007/s10120-013-0253-y

Cited by 31 publications

(50 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Helicobacter pylori infection is the primary cause of GC incidence, and several lifestyles are independently associated with GC risk, such as alcohol, smoking, and weight [3,4]. Curative surgeries and adjuvant chemotherapies are considered as acceptable intervention for GC treatment [5,6]. The treatment outcomes of GC decide by diagnosis duration, and good outcomes often occur under conditions of diagnosis at an early stage of GC [7].…”

Section: Introductionmentioning

confidence: 99%

Effect of expressions of tumor necrosis factor α and interleukin 1B on peritoneal metastasis of gastric cancer

Guo

Zhang

et al. 2015

Tumor Biol.

View full text Add to dashboard Cite

Our study aimed to investigate effect of expressions of tumor necrosis factor α (TNF-α) and interleukin 1B (IL-1B) on peritoneal metastasis of gastric cancer (GC). From June 2012 to June 2014, a total of 60 patients with advanced peritoneal metastasis from GC were collected from Department of Gastrointestinal and Nutriology Surgery at Shengjing Hospital of China Medical University. Furthermore, 60 GC patients without peritoneal metastasis were enrolled as controls. Immunohistochemistry was performed to test TNF-α and IL-1B expression, and logistic regression analysis was employed for evaluating risk factors for peritoneal metastasis of GC. Our results showed that TNF-α expression in metastatic group and non-metastatic group was significantly different (P = 0.043), but no significant difference was found in IL-1B expression between two groups (P = 0.261). In addition, TNF-α expression in metastatic group and non-metastatic group was associated with tumor size, depth of invasion, the degree of differentiation (all P < 0.05). Logistic regression analysis indicated that tumor size, depth of invasion, the degree of differentiation and TNF-α expression were risk factors for peritoneal metastasis of GC (all P < 0.05). Our study found that TNF-α expression may play a vital role in peritoneal metastasis of GC, while IL-1B expression might not be correlated with peritoneal metastasis.

show abstract

Section: Introductionmentioning

confidence: 99%

Effect of expressions of tumor necrosis factor α and interleukin 1B on peritoneal metastasis of gastric cancer

Guo

Zhang

et al. 2015

Tumor Biol.

View full text Add to dashboard Cite

show abstract

“…The macroscopic high-risk group included more patients with higher pathological T ( P = 0.0025), and higher 13 th JGCA pathological stage ( P = 0.0004), while there were no significant differences in pN distribution and lymph node dissection level between the macroscopic high-risk group and the average-risk group. In our previous reports, lymph node dissection level was proven not to affect prognosis in these 172 cases[11]. …”

Section: Resultsmentioning

confidence: 92%

“…A total of 396 patients with 13 th Japanese Gastric Cancer Association (JGCA) stage II/III advanced gastric cancer underwent curative gastrectomy with D1-D2 lymph node dissection, and 67 underwent neoadjuvant chemotherapy or postoperative chemotherapy other than S-1 as previously reported[11-13]. Advanced gastric cancer was defined as pathological T2 (13 th JGCA stage) or beyond, and pT1 gastric cancers were excluded from this study even when they were pathological stage II.…”

Section: Methodsmentioning

confidence: 99%

“…Advanced gastric cancer was defined as pathological T2 (13 th JGCA stage) or beyond, and pT1 gastric cancers were excluded from this study even when they were pathological stage II. Older age, defined as 67 years of age or older was used from a prognostic point of view from the previous reports[11]. Among the 329 patients with pStage II/III, 172 agreed to undergo adjuvant S-1 therapy after curative resection.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Macroscopic appearance of Type IV and giant Type III is a high risk for a poor prognosis in pathological stage II/III advanced gastric cancer with postoperative adjuvant chemotherapy

Yamashita¹,

Ema²,

Hosoda³

et al. 2017

WJGO

Self Cite

View full text Add to dashboard Cite

AIMTo evaluate whether a high risk macroscopic appearance (Type IV and giant Type III) is associated with a dismal prognosis after curative surgery, because its prognostic relevance remains elusive in pathological stage II/III (pStage II/III) gastric cancer.METHODSOne hundred and seventy-two advanced gastric cancer (defined as pT2 or beyond) patients with pStage II/III who underwent curative surgery plus adjuvant S1 chemotherapy were evaluated, and the prognostic relevance of a high-risk macroscopic appearance was examined.RESULTSAdvanced gastric cancers with a high-risk macroscopic appearance were retrospectively identified by preoperative recorded images. A high-risk macroscopic appearance showed a significantly worse relapse free survival (RFS) (35.7%) and overall survival (OS) (34%) than an average risk appearance (P = 0.0003 and P < 0.0001, respectively). A high-risk macroscopic appearance was significantly associated with the 13th Japanese Gastric Cancer Association (JGCA) pT (P = 0.01), but not with the 13th JGCA pN. On univariate analysis for RFS and OS, prognostic factors included 13th JGCA pStage (P < 0.0001) and other clinicopathological factors including macroscopic appearance. A multivariate Cox proportional hazards model for univariate prognostic factors identified high-risk macroscopic appearance (P = 0.036, HR = 2.29 for RFS and P = 0.021, HR = 2.74 for OS) as an independent prognostic indicator.CONCLUSIONA high-risk macroscopic appearance was associated with a poor prognosis, and it could be a prognostic factor independent of 13th JGCA stage in pStage II/III advanced gastric cancer.

show abstract

“…The prognostic significance of a number of clinical parameters has been examined for patients with GC subsequent to radical surgery (8)(9)(10)(11)(12)(13)(14)(15). Of these, the preoperative prognostic nutritional index (PNI) as a reflection of the immunological and nutritional condition of the patients has been associated with the outcomes of patients who undergo gastrectomy for a number of stages of GC (10,11,16,17).…”

Section: Introductionmentioning

confidence: 99%

Outcome predictors for patients with stage II/III gastric cancer who undergo gastrectomy and S-1 adjuvant chemotherapy

et al. 2017

View full text Add to dashboard Cite

Abstract. Predictors of survival in patients with stage II/III gastric cancer (GC) who received tegafur/gimeracil/oteracil (S-1) adjuvant chemotherapy (ACT) subsequent to gastrectomy were examined. Additionally, the association between dose intensity of S-1 and survival rate was investigated. A total of 62 patients with stage II/III gastric cancer were retrospectively evaluated, each of whom had received a curative D2 gastrectomy and S-1 ACT. The relative performance (RP; administered/planned S-1 doses x100%), body mass index (BMI), prognostic nutritional index (PNI) and body weight (BW) were calculated, and the association of survival with these factors and other clinicopathological parameters was examined. The 1-year treatment continuation rate for S-1 was 94.2%, excluding patients who experienced cancer recurrences during their ACT year. The initial S-1 reduction rate was 38.7%. Patients with stage II/IIIA disease exhibited significantly improved 5-year overall survival rates compared with patients with stage IIIB GC, 81.6/73.7 vs. 33.8% (P<0.01). No association between RP and survival was observed. BMI, BW and PNI were significantly decreased following surgery compared with preoperative states. In the univariate analysis, postoperative BW loss (BMI loss), pathological stage and >7 lymph node metastases were significantly associated with outcome (P<0.05); in the multivariate analysis, postoperative BW loss >10.6% and pathological stages were independent prognostic factors for survival. Continuing S-1 ACT for the full year exhibited a greater effect on survival compared with dosage. Early postoperative nutritional deterioration may decrease the survival rates in these patients.

show abstract

Lymph node ratio is a critical prognostic predictor in gastric cancer treated with S-1 chemotherapy

Cited by 31 publications

References 23 publications

Effect of expressions of tumor necrosis factor α and interleukin 1B on peritoneal metastasis of gastric cancer

Effect of expressions of tumor necrosis factor α and interleukin 1B on peritoneal metastasis of gastric cancer

Macroscopic appearance of Type IV and giant Type III is a high risk for a poor prognosis in pathological stage II/III advanced gastric cancer with postoperative adjuvant chemotherapy

Outcome predictors for patients with stage II/III gastric cancer who undergo gastrectomy and S-1 adjuvant chemotherapy

Contact Info

Product

Resources

About